They target soluble and insoluble forms of pathological Aβ, resulting in reduced Aβ levels in the brain of patients with AD and decreased levels of phosphorylated tau in the CSF and blood.276, 277, 278, 279, 280, 281 While treatment with lecanemab and donanemab improves cognitive decline,277,278,280, 281, 282 the efficacy of aducanumab treatment on cognition has been inconsistent in clinical trials.276. The gene discussed is MAPT; the disease is Alzheimer disease.